SCHEMBL2164699

SCHEMBL2164699

Fc1cc(Nc2nnnc3ccccc23)ccc1Br

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
RAB9A P51151 1/20 0.57
KMT2A Q03164 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
PTGS2 P35354 1/20 0.47
EGFR P00533 3/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ABCG2 Q9UNQ0 11/20 0.42
MET P08581 1/20 0.40
KDR P35968 1/20 0.40
ABCB1 P08183 2/20 0.40
ABCC1 P33527 1/20 0.40
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2164231 0.81 EGFR (0.67) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL12401609 0.81 MEN1 (0.57) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL2164245 0.79 MEN1 (0.70) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL2163667 0.78 MEN1 (0.65) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL2163688 0.78 MEN1 (0.60) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL3757318 0.75 MEN1 (0.69) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL3757886 0.74 MEN1 (0.68) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL2163686 0.74 EGFR (0.44) MEN1KMT2AEGFR
SCHEMBL2163490 0.73 RAB9A (0.54) MEN1RAB9AKMT2ACTDSP1TDP1
SCHEMBL2164209 0.72 EGFR (0.65) MEN1RAB9AKMT2ACTDSP1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 MEN1 2848/4885RAB9A 3093/4885KMT2A 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.